RecruitingNot Applicable

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Iraq120 participantsStarted 2025-10-10

Plain-language summary

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

Who can participate

Age range

18 Years – 45 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Serum sFlt-1 concentration

Timeframe: At enrollment (20-36 weeks of gestation)

Serum PlGF concentration

Timeframe: At enrollment (20-36 weeks of gestation)

sFlt-1/PlGF ratio

Timeframe: At enrollment (20-36 weeks of gestation)

Serum Osteoprotegerin (OPG) concentration

Timeframe: At enrollment (20-36 weeks of gestation)

Serum sENG(Souble Endoglin) concentration

Timeframe: At enrollment (20-36 weeks of gestation)

Trial details

NCT IDNCT07349277

SponsorAmmar Jassim Abed

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-30

Contact for this trial

Ammar Jassim Abed, MSc

+9647809561105 ammar.jassim11@gmail.com

View on ClinicalTrials.gov More Preeclampsia trials

Plain-language summary

Who can participate

Age range

18 Years – 45 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Serum sFlt-1 concentration

Timeframe: At enrollment (20-36 weeks of gestation)

Serum PlGF concentration

Timeframe: At enrollment (20-36 weeks of gestation)

sFlt-1/PlGF ratio

Timeframe: At enrollment (20-36 weeks of gestation)

Serum Osteoprotegerin (OPG) concentration

Timeframe: At enrollment (20-36 weeks of gestation)

Serum sENG(Souble Endoglin) concentration

Timeframe: At enrollment (20-36 weeks of gestation)